1. Home
  2. ENTX vs JYNT Comparison

ENTX vs JYNT Comparison

Compare ENTX & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$2.37

Market Cap

142.0M

Sector

Health Care

ML Signal

HOLD

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.32

Market Cap

149.5M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
JYNT
Founded
2010
2010
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Multi-Sector Companies
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
142.0M
149.5M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
ENTX
JYNT
Price
$2.37
$8.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$10.00
$17.00
AVG Volume (30 Days)
107.9K
139.7K
Earning Date
11-14-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$124,000.00
$54,176,002.00
Revenue This Year
N/A
$7.70
Revenue Next Year
N/A
$10.24
P/E Ratio
N/A
N/A
Revenue Growth
25.25
10.47
52 Week Low
$1.50
$7.50
52 Week High
$3.22
$13.47

Technical Indicators

Market Signals
Indicator
ENTX
JYNT
Relative Strength Index (RSI) 39.09 47.79
Support Level $2.26 $8.18
Resistance Level $2.53 $8.64
Average True Range (ATR) 0.23 0.29
MACD -0.07 0.06
Stochastic Oscillator 6.05 64.24

Price Performance

Historical Comparison
ENTX
JYNT

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

Share on Social Networks: